Prescription Drug Price Relief Act of 2025
This act aims to lower prescription drug prices in the U.S. It establishes a process to identify excessively priced drugs by comparing them to prices in other countries. If a drug's price is deemed excessive, the government can revoke the manufacturer's exclusive rights, allowing other companies to produce cheaper generic versions. This is intended to increase drug accessibility and reduce costs for patients.
Key points
The government will regularly review brand-name drug prices, comparing them to prices in Canada, the UK, Germany, France, and Japan.
If a drug's price in the U.S. is significantly higher than the median in these countries, the manufacturer may lose its exclusive production rights.
Loss of exclusivity means other companies can produce cheaper versions of the drug, aiming to reduce costs for patients.
The act includes financial penalties for manufacturers who fail to report required drug pricing data or provide false information.
A public database will be created, allowing anyone to check which drugs are deemed excessively priced and if cheaper alternatives are available.
Introduced
Citizen Poll